Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464450 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
A Phase 1 study of Healthy Participants and Pharmacokinetics, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT01464450 is a Phase 1 study of Healthy Participants and Pharmacokinetics that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 55 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01464450, a Phase 1 study of Healthy Participants and Pharmacokinetics, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to learn about the relative bioavailability (the extent to which the drug becomes available to the body) and pharmacokinetics (blood levels) of rivaroxaban in healthy participants after receiving a 20 mg rivaroxaban tablet orally as a whole tablet, crushed and mixed in applesauce, and as a suspension through a Naso-gastric (NG) tube. The relative bioavailability of rivaroxaban may be different when given as a crushed tablet compared with an intact (whole) tablet and when given via an NG tube. The safety and tolerability of rivaroxaban will also be assessed.
Conditions Studied
Interventions
- DRUG Rivaroxaban
Study Locations (1)
New Jersey
- - Neptune City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2011-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464450
The ClinicalTrials.gov registry entry for NCT01464450 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (15% lower). The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which Rivaroxaban is the first listed.
NCT01464450 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01464450 about?
NCT01464450 is a clinical study titled "Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants". The primary objective of this study is to learn about the relative bioavailability (the extent to which the drug becomes available to the body) and pharmacokinetics (blood levels) of rivaroxaban in healthy participants after receiving a 20 mg rivaroxaban tablet orally as a whole tablet, crushed and ...
What is the current status of trial NCT01464450?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2011-10. Estimated completion is 2011-12.
What conditions does trial NCT01464450 study?
This clinical trial studies the following conditions: Healthy Participants, Pharmacokinetics, Bioavailability.
What interventions are being tested in trial NCT01464450?
The interventions under investigation include: Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT01464450?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01464450 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.